

The Amgen Safety Net Foundation is a nonprofit patient assistance program that helps qualifying uninsured patients access Amgen medicines at no cost. Products supported by the Amgen Safety Net Foundation covers Aranesp® (darbepoetin), EPOGEN® (epoetin) for dialysis use only, Neulasta® (pegfilgrastim), NEUPOGEN® (filgrastim), Nplate® (romiplostim), Prolia® (denosumab) injection, Sensipar® (cinacalcet), Vectibix® (panitumumab) injection, and XGEVA® (denosumab).
Therapies Offered
-
Aimovig™
-
Aranesp® (darbepoetin alfa)
-
BLINCYTO® (blinatumomab) for injection
-
Corlanor® (ivabradine) tablets
-
Enbrel® (etanercept)
-
EPOGEN® (EPOETIN ALFA) for dialysis use only
-
IMLYGIC® (talimogene laherparepvec) suspension for injection
-
Kyprolis® (carfilzomib) for injection
-
Neulasta Disposal Container
-
Neulasta® (pegfilgrastim)
-
Neupogen®
-
Nplate® (romiplostim)
-
Parsabiv™
-
Prolia® (denosumab) injection for bone health
-
Prolia® (denosumab) injection for bone health and oncology
-
Repatha Disposal Container
-
Repatha® (evolocumab)
-
Sensipar® (cinacalcet)
-
Vectibix® (panitumumab) injection
-
XGEVA® (denosumab)
The information provided on this page was provided by The Safety Net Foundation. For information about specific prescription drugs, including the FDA-approved prescribing information, please visit www.amgen.com.